Baricitinib in chronic kidney disease: an exploratory analysis integrating network toxicology, molecular docking and pharmacovigilance
Baricitinib has computational and mechanistic potential to modulate key pathways in CKD. Pharmacovigilance data confirm risks of infection and thrombosis but show no disproportionate renal safety signal. These exploratory findings generate a testable hypothesis for its use in CKD, underscoring the necessity of prospective, renal-function-stratified trials.
Authors
- Miao Deng (ORCID: https://orcid.org/0000-0002-5566-4811)
- Zhixun Bai (ORCID: https://orcid.org/0000-0003-4352-0658)
- Rubin. Zheng
- Qin Wang
- Ye Liu
- Liangdong Yuan
- Jiaxi Chen
- Jinfen Han
- Jing Lu
- Jiayi Lyu
Institutions
- Zunyi Medical University (CN)
- Minzu Normal University of Xingyi (CN)
- Guizhou Provincial People's Hospital (CN)
- Affiliated Hospital of Jining Medical University (CN)
- Affiliated Hospital of Zunyi Medical College (CN)
Publication Details
- Journal
- Frontiers in Medicine
- Published
- 2026-01-09
- DOI
- https://doi.org/10.3389/fmed.2025.1717739
- Primary Topic
- Rheumatoid Arthritis Research and Therapies
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Jining Medical University